Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis reveals AI-guided therapy improves outcomes for intermediate-risk prostate cancer, suggesting a shift in treatment practices.
The ArteraAI Prostate Test (ArteraAI Inc.) is the first predictive biomarker for benefit of adding short-term androgen deprivation therapy (ADT) to radiotherapy for intermediate-risk prostate cancer. We evaluated the cost-effectiveness of ArteraAI to guide short-term ADT with a Markov model simulating 15-year outcomes for 71-year-old patients with intermediate-risk prostate cancer receiving radiotherapy using NRG/RTOG 9408 data on which ArteraAI was validated. Three strategies were compared: 1) all patients receive ADT (ADT-for-all), 2) only patients with unfavorable intermediate-risk prostate cancer receive ADT (National Comprehensive Cancer Network [NCCN]), and 3) only ArteraAI-positive patients receive ADT (ArteraAI). Costs and utilities obtained from Medicare claims and published literature were used to calculate incremental cost-effectiveness ratios (ICERs). A willingness-to-pay threshold of $100,000/QALY was chosen. The ADT-for-all strategy was dominated by the NCCN strategy. Compared with the NCCN strategy, the ArteraAI strategy lowered costs by $12,296 and improved effectiveness by 0.01 QALYs, and thus was dominant.
No takes yet. Share an insight, caveat, or question.
Courtney et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: